Abstract
Parathyroid carcinoma is a rare malignant endocrine tumor accounting for only 0.5% to 5% of all primary hyperparathyroidism. Among these malignancies, only 10-25% are nonfunctioning. After the review of the literature we could only ascertain a number of 25 cases reported worldwide, since 1929, our case being the 26th, but the first with a very aggressive pathology, treated with chemotherapy scheme usually used for neuroendocrine tumors. Considering these facts, every single case presented is a step forward in defying the clinical presentation, for the awareness of the clinicians, and also in establishing standard adjuvant therapies.
Highlights
Parathyroid carcinoma is a rare malignant endocrine tumor accounting for only 0.5% to 5% of all primary hyperparathyroidism
Letters to the Editor Parathyroid carcinoma is one of the very rare malignant endocrine tumors accounting for only 0.5% to 5% of all primary hyperparathyroidism [1]
The present case is the 26th, being the first with a very aggressive pathology, treated with chemotherapy scheme usually used in the therapy of neuroendocrine tumors
Summary
Parathyroid carcinoma is a rare malignant endocrine tumor accounting for only 0.5% to 5% of all primary hyperparathyroidism. Letters to the Editor Parathyroid carcinoma is one of the very rare malignant endocrine tumors accounting for only 0.5% to 5% of all primary hyperparathyroidism [1]. Only 10-25% are nonfunctioning [2], with normal values of parathyroid hormone (PTH).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.